Iqvia (NYSE:IQV) Price Target Raised to $181.00 at Robert W. Baird

Iqvia (NYSE:IQV) had its target price upped by stock analysts at Robert W. Baird from $172.00 to $181.00 in a report issued on Thursday, BenzingaRatingsTable reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target suggests a potential upside of 8.96% from the stock’s current price.

A number of other research firms also recently commented on IQV. Stifel Nicolaus lifted their price objective on shares of Iqvia from to and gave the stock a “buy” rating in a report on Wednesday. Wells Fargo & Co initiated coverage on shares of Iqvia in a report on Tuesday, January 7th. They issued an “overweight” rating and a $180.00 price objective for the company. ValuEngine downgraded shares of Iqvia from a “hold” rating to a “sell” rating in a report on Tuesday, February 4th. Zacks Investment Research raised shares of Iqvia from a “sell” rating to a “hold” rating and set a $170.00 price target for the company in a report on Tuesday, February 4th. Finally, Credit Suisse Group reissued a “buy” rating and set a $170.00 price target on shares of Iqvia in a report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $174.96.

Iqvia stock opened at $166.11 on Thursday. The company has a market cap of $31.03 billion, a PE ratio of 136.16, a P/E/G ratio of 1.70 and a beta of 0.91. The company has a fifty day moving average price of $157.77 and a two-hundred day moving average price of $151.66. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.12. Iqvia has a 12 month low of $130.18 and a 12 month high of $169.14.

Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 12th. The medical research company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.85 billion. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The firm’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.50 earnings per share. Equities research analysts anticipate that Iqvia will post 5.9 earnings per share for the current year.

In related news, Director Michael J. Evanisko sold 6,250 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $160.76, for a total value of $1,004,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael R. Mcdonnell sold 12,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the completion of the sale, the chief financial officer now directly owns 14,366 shares of the company’s stock, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,000 shares of company stock valued at $5,830,215. Corporate insiders own 6.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. AlphaCrest Capital Management LLC lifted its holdings in Iqvia by 210.8% in the fourth quarter. AlphaCrest Capital Management LLC now owns 7,752 shares of the medical research company’s stock worth $1,198,000 after purchasing an additional 5,258 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in Iqvia by 3.2% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 39,437 shares of the medical research company’s stock worth $6,093,000 after purchasing an additional 1,241 shares during the period. Credit Suisse AG lifted its holdings in Iqvia by 5.1% in the fourth quarter. Credit Suisse AG now owns 639,542 shares of the medical research company’s stock worth $98,816,000 after purchasing an additional 31,273 shares during the period. ERTS Wealth Advisors LLC acquired a new stake in Iqvia in the fourth quarter worth about $46,000. Finally, Bank of Marin acquired a new stake in Iqvia in the fourth quarter worth about $815,000. 89.93% of the stock is owned by institutional investors and hedge funds.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.